Clodronate improves bone mineral density in postmenopausal breast cancer patients treated with adjuvant antioestrogens

British Journal of Cancer

Volumn 75, Issue 4, 1997, Pages 602-605

  Saarto, T ^a   Blomqvist, C ^a   Valimaki M ^b   Makela P ^b   Sarna, S ^a   Elomaa, I ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Antioestrogens; Bisphosphonate; Bone mineral density; Breast neoplasm; Post menopausal osteoporosis; Toremifene

Indexed keywords

ANTIESTROGEN; CALCIUM CHANNEL AFFECTING AGENT; CLODRONIC ACID; TAMOXIFEN; TOREMIFENE;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MINERAL; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0031045147     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.105     Document Type: Article

References (24)

1. Chesnut III C (1984) Treatment of postmenopausal osteoporosis. Compr Ther 10: 41-47
2. Di Salle E, Zaccheo T and Ornati G (1990) Antiestrogenic and antitumor properties of the new triphenylethylene derivative toremifene in the rat. J Steroid Biochem 36: 203-206
3. Early Breast Cancer Trialists' Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1-15, 72-85
4. Elomaa I, Blomqvist C, Grohn P, Porkka L, Kairento AI, Selander K, Lamberg Ac and Holmstrom T (1983) Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet 1: 146-149
5. Ettinger B, Genant HK and Cann CE (1987) Postmenopausal bone loss is prevented by treatment with low-dosage estrogen with calcium. Ann Intern Med 106: 40-45
6. Ettinger B, Genant HK, Steiger P and Madvig P (1992) Low-dosage micronized 17 beta-estradiol prevents bone loss in postmenopausal women. Am J Obstet Gynecol 166: 479-488
7. Filipponi P, Pedetti M, Fedeli L, Cini L, Palumbo R, Boldrini S, Massoni C and Cristallini S (1995) Cyclic clodronate is effective in preventing postmenopausal bone loss: A comparative study with transcutaneous hormone replacement therapy. J Bone Miner Res 10: 697-703
8. Genant HK, Baylink DJ, Gallagher JC, Harris ST, Steiger P and Herber M (1990) Effect of estrone sulfate on postmenopausal bone loss. Obstet Gynecol 76: 579-584
9. Giannini S, D'Angelo A, Malvasi L, Castrignano R, Pati T, Tronca R, Liberto L, Nobile M and Crepaldi G (1993) Effects of one-year cyclical treatment with clodronate on postmenopausal bone loss. Bone 14: 137-141
10. Harris ST, Watts NB, Jackson RD, Genant HK, Wasnich RD, Ross P, Miller PD, Licata AA and Chesnut III C (1993) Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med 95: 557-567
11. Kristensen B, Ejlertsen B, Dalgaard P, Larsen L, Holmegaard SN, Transbol I and Mouridsen HT (1994) Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. J Clin Oncol 12: 992-997
12. Liberman UR, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW, Dequeker J, Favus M, Seeman E, Recker RR, Capizza T, Santora AC, Lombardi A, Shah RV, Hirsch LJ and Karpf DB (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333: 1437-1443
13. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, Carbone PP and Demets DL (1992) Effects of tamoxifen on hone mineral density in postmenopausal women with breast cancer. N Engl J Med 326: 852-856
14. Martoni A, Guaraldi M, Camera P, Biagi R, Marri S, Beghe F and Pannuti F (1991) Controlled clinical study on the use of dichloromethylene diphosphonate in patients with metastasizing to skeleton. Oncology 48: 97-101
15. Paterson AH, Powles TJ, Kanis JA, Mccloskey E, Hanson J and Ashley S (1993) Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11: 59-65
16. Powles TJ, Hickish T, Kanis JA, Tidy A and Ashley S (1996) Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14: 78-84
17. Reginster JY, Lecart MP, Deroisy R, Sarlet N, Denis D, Ethgen D, Collette J and Franchimont P (1989) Prevention of postmenopausal bone loss by tiludronate. Lancet 2: 1469-1471
18. Reid IR, Wattie DJ, Evans MC, Gamble GD, Stapleton JP and Cornish J (1994) Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis. J Clin Endocrinol Metab 79: 1595-1599
19. Stevenson JC, Cust MP, Gangar KF, Hillard TC, Lees B and Whitehead MI (1990) Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopasual women. Lancet 336: 265-269
20. Storm T, Thamsborg G, Steiniche T, Genant HK and Sorensen OH (1990) Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 322: 1265-1271
21. Valavaara R, Pyrhonen S, Heikkinen M, Rissanen P, Blanco G, Tholix E, Nordman E, Taskinen P, Holsti L and Hajba A (1988) Toremifene, a new antiestrogenic compound, for treatment of advanced breast cancer. Phase II study. Eur J Cancer Clin Oncol 24: 785-790
22. Van Holten Verzantvoort ATM, Kroon HM, Bijvoet OL, Cleton FJ, Beex LV, Blijham G, Hermans J, Neijt JP, Papapoulos SE, Sleeboom HP, Vermey P and Zwinderman AH (1993) Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol 11: 491-498
23. Ward RL, Morgan G, Dalley D and Kelly PJ (1993) Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women. Bone Miner 22: 87-94
24. Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson G, Yanover MJ, Mysiw WJ, Kohse L, Rao B, Steigner P, Richmond B and Chesnut III CH (1990) Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 323: 73-79